Table 3 The association between TRIM25, BRD7 expression, and clinicopathologic features of breast cancer.

From: TRIM25 degrades BRD7 protein stability through the ubiquitin proteasome pathway to promote breast cancer progression and paclitaxel resistance by activating YB1/Bcl-2 transcription axis

Variables

TRIM25 expression

  

TRIM25/BRD7 expression

 

Features

TRIM25L

TRIM25H

P

 

TRIM25LBRD7H

TRIM25HBRD7L

P

 

(102)

(117)

 

(61)

(60)

Age (Y [%])

       

 ≤46

51 (50.00%)

60 (49.43%)

0.8499

 

27 (44.26%)

27 (45.00%)

0.9350

 >46

51 (50.00%)

57 (50.57%)

 

34 (55.74%)

33 (55.00%)

Tumor size (n[%])

       

 T1-2

72 (70.59%)

52 (44.44%)

0.0001

***

 

43 (70.49%)

24 (40.00%)

0.0007

***

 T3-4

30 (29.41%)

64 (54.70%)

 

18 (29.51%)

36 (60.00%)

N (n[%])

       

 Absent

30 (29.41%)

23 (19.66%)

0.9998

 

19 (31.15%)

9 (15.00%)

0.0352

**

 Present

70 (70.59%)

93 (79.49%)

 

42 (68.85%)

51 (85.00%)

M (n[%])

       

 Absent

101 (99.02%)

97 (82.91%)

0.0001

***

 

60 (98.36%)

49 (81.67%)

0.0021

**

 Present

1 (1.08%)

18 (15.39%)

 

1 (1.64%)

11 (18.33%)

Stage (n[%])

       

 Ⅰ-Ⅱ

76 (74.51%)

50 (42.73%)

P < 0.001

***

 

45 (73.77%)

23 (38.33%)

0.0109*

 Ⅲ-Ⅳ

26 (25.49%)

66 (56.41%)

 

16 (26.23%)

37 (61.67%)

  1. In 219 patients, Tumor size, lymph node metastasis, and clinical stage were not detected in one of the patients with high TRIM25 expression; distant metastasis was not detected in two of the patients with high TRIM25 expression. The median of TRIM25 expression or BRD7 expression was used as the cutoff value. Y Year, TNM Tumor-node-metastases, H High expression, L Low expression, P P values of two-sided χ2 test, % The ratio of the number of samples to the total number of samples per column, * P < 0.05, ** P < 0.01, *** P < 0.001.
Back to article page